DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

Quick facts

Phase 2 pipeline

• DC-806 · Inflammatory diseases
  DC-806 is an anti-inflammatory monoclonal antibody targeting the IL-17 receptor.

Phase 1 pipeline

• [14C]-DC-806

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company portfolio CI brief
• DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company pipeline updates RSS

Related

• Sector hub: All tracked pharma companies